Marinus Pharmaceuticals, Inc.
NASDAQ: MRNS0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Scott N. Braunstein
- Employees
- 165
- Headquarters
- Radnor, United States
- IPO year
- 2014
- Market cap
- $30.4M
- Website
- https://marinuspharma.com
Loading MRNS…
Loading profile data…Frequently asked questions about MRNS
What does Marinus Pharmaceuticals, Inc. (MRNS) do?
Marinus Pharmaceuticals, Inc. is a specialized biopharmaceutical firm dedicated to the development and commercialization of therapeutic solutions for individuals suffering from rare genetic epilepsies and other seizure-related conditions. The company's primary commercialized product is ZTALMY, an oral suspension specifically designed to manage s...
Where does MRNS trade?
Marinus Pharmaceuticals, Inc. (MRNS) trades on the NASDAQ Global Market.
What sector is MRNS in?
Marinus Pharmaceuticals, Inc. (MRNS) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Marinus Pharmaceuticals, Inc.?
Scott N. Braunstein is the chief executive officer of Marinus Pharmaceuticals, Inc. (MRNS).
Where is Marinus Pharmaceuticals, Inc. headquartered?
Marinus Pharmaceuticals, Inc. is headquartered in United States.
Does MRNS pay a dividend?
Marinus Pharmaceuticals, Inc. (MRNS) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did MRNS go public?
Marinus Pharmaceuticals, Inc. (MRNS) completed its initial public offering in 2014.